Shaanxi Meibang Pharmaceutical Group Co Ltd (605033) — Cash Flow Reinvestment Rate

Latest as of September 2025: 0.19x

Shaanxi Meibang Pharmaceutical Group Co Ltd (605033) has a Cash Flow Reinvestment Rate of 0.19x as of September 2025, reinvesting CN¥54.40 Million (capex CN¥54.40 Million ) from operating cash flow of CN¥281.88 Million. Check how high is Shaanxi Meibang Pharmaceutical Group Co 's earnings quality to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

0.19x
(Capex + Investments) / Operating CF

Total Reinvested

CN¥54.40 Million
Capex + Investments

Operating Cash Flow

CN¥281.88 Million
CNY

Capital Expenditures

CN¥54.40 Million
CNY

Shaanxi Meibang Pharmaceutical Group Co Ltd Cash Flow Reinvestment Rate (2017–2024)

Historical reinvestment intensity for Shaanxi Meibang Pharmaceutical Group Co Ltd across 7 annual periods. Explore Shaanxi Meibang Pharmaceutical Group Co cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for Shaanxi Meibang Pharmaceutical Group Co Ltd (2017–2024)

Year-by-year capital reinvestment analysis for Shaanxi Meibang Pharmaceutical Group Co Ltd. For live market cap and broader valuation context, see market value of Shaanxi Meibang Pharmaceutical Group Co .

Year Reinvestment Rate Total Reinvested (CNY) Operating CF Capex YoY Change
2024 1.92x CN¥539.05 Million CN¥280.40 Million CN¥158.81 Million ▲ +123.3%
2023 0.86x CN¥288.20 Million CN¥334.79 Million CN¥203.69 Million ▼ -24.3%
2022 1.14x CN¥143.69 Million CN¥126.41 Million CN¥109.29 Million ▼ -19.1%
2020 1.40x CN¥105.20 Million CN¥74.88 Million CN¥61.71 Million ▲ +218.4%
2019 0.44x CN¥56.69 Million CN¥128.45 Million CN¥33.78 Million ▼ -78.5%
2018 2.06x CN¥34.86 Million CN¥16.96 Million CN¥34.86 Million ▲ +244.2%
2017 0.60x CN¥17.56 Million CN¥29.41 Million CN¥17.56 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow